ArticleParasitology research2015
Efficiency of liposomal albendazole for the treatment of the patients with complex alveolar echinococcosis: a comparative analysis of CEUS, CT, and PET/CT.
Article in Parasitology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 29 citations in OpenAlex.
- Advances in Novel Diagnostic Techniques for Alveolar Echinococcosis.Diagnostics (Basel, Switzerland) · 2025Review
- Chemotherapy for the treatment of alveolar echinococcosis: Where are we?Parasite (Paris, France) · 2024Review
- LncRNA Regulation Mechanism in Hepatic Alveolar Echinococcosis with Nanosecond Pulse.Acta parasitologica · 2023Article
- Quantitative evaluation of range and metabolic activity of hepatic alveolar echinococcosis lesion microenvironment using PET/CT and multi-site sampling method.BMC infectious diseases · 2021Article
- Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography.Scientific reports · 2020Article
- Synthesis and characterization of mesoporous SBA-15 and SBA-16 as carriers to improve albendazole dissolution rate.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- Plasma IL-23 and IL-5 as surrogate markers of lesion metabolic activity in patients with hepatic alveolar echinococcosis.Scientific reports · 2018Article
- Article
- Management of Advanced Hepatic Alveolar Echinococcosis: Report of 42 Cases.The American journal of tropical medicine and hygiene · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aim to investigate the efficiency of liposomal albendazole (L-ABZ) for the treatment of complex alveolar echinococcosis (CAE) using contrast-enhanced ultrasonography (CEUS), computed tomography (CT), and positron emission tomography (PET)/CT. Twelve patients with CAE admitted to our hospital between June 2000 and June 2011 were included in this retrospective study. CEUS, CT, and PET/CT were used to evaluate the clinical efficiency of L-ABZ for these patients. Effectiveness was defined as significant response after chemotherapy. Effectiveness with clinical significance was defined as complete response after chemotherapy, and non-effectiveness was defined as no response after chemotherapy. Patients were followed up for 3-11 years. Ten patients (83.3%) had a ratio of averaged gray scale in the enhanced band to that of hepatic tissues of ≤1.1, and six patients (50.0%) had a ratio of ≤0.9 as revealed by CEUS. CT scanning results indicated an effective rate of 91.6%. PET/CT indicated a maximal standard uptake (SUVmax) of <2.5 in nine patients (75.0%), which was considered to be effective. A high uptake of fluorodeoxyglucose was observed in three patients (25.0%) with SUVmax ≥2.5, which was considered to be non-effective. Taken together, CEUS, CT, and PET/CT provide objective evaluation of the clinical efficiency of L-ABZ for the treatment of CAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.